Compounds 3c2, 2d1, 3d1, 2f2, 3f2, and 4a4 were not able to in duce HEXIM1 expression, at 100 lM. However, compounds 3a2 and 3d2 showed significant activity at 100 lM that was not ob served at 500 lM. The variation in potency could be due to the pre cipitation of the two compounds at 500 lM, which hampers cell penetration. Compounds 3b1 and 3b2 with the aromatic ring at B moiety showed good activity at 100 lM, and induced HEXIM1 expression by 3.8 and 2 fold, respectively. Compounds 2a4, 2a5, and 4a1 exhibited reduced activity at lower concentrations, sug gesting dose dependent stimulation of HEXIM1 expression by these compounds. Due to the unsymmetrical structural character istics of 4a1, a dose dependent study was performed and the re sults are presented in Figure 4 . The compound dose dependently induced HEXIM1 expression suggesting that the unsymmetrical structure and increased hydrophobicity contribute to improved biological activity. Considering the aromatic moiety of compounds 3b1 and 3b2 and the bulky terminal moiety of compounds 2a4 and 2a5, more potent analogs could be developed if several of these structural units are combined in the new drug design.
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In brief, our findings have provided unique molecular scaffolds that significantly induced HEXIM1 expression in prostate cancer cells, and have opened a new lead optimization direction of HMBA. To the best of our knowledge, this is the first study focusing on the lead optimization of HMBA to generate more potent HEXIM1 inducers. The results support the potential of unsymmetrical HMBA derivatives as lead compounds. More potent HEXIM1 induc ers have potential application in cancer, AIDS, and heart disease treatment. Further lead optimization of HMBA to generate more potent HEXIM1 inducers is currently underway in our laboratory.
